Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Portage Biotech to $18 from $26 on updated risk environment, while keeping an Outperform rating on the shares following Q2 results. The analyst notes Portage has made a sizeable investment in building out what he believes is one of the most extensive portfolios of adenosine receptor antagonists out there.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRTG:
- Portage Biotech reports Q4 EPS (6c), consensus (29c)
- Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
- Portage Biotech participates in a conference call with Cantor Fitzgerald
- Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- Portage Biotech management to meet virtually with Oppenheimer
